CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

This overlap is largely why VUG has outperformed the S&P 500 over the years. These have been some of the best-performing stocks on th ...

We are off to a strong start this third-quarter earnings season. Not only are most companies comfortably surpassing estimates ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

That's why Visa has few direct competitors of note. And the company still sees a massive worldwide opportunity. The stock looks likely to perform well, and even better than the S&P 500, through the ...

CRISPR Therapeutics (NASDAQ:CRSP) has filed a prospectus supplement with the U.S. SEC to sell up to $600 million worth of its common shares through Jefferies LLC, acting as its sales agent. The sale ...

Companies split their stocks to make it easier for retail investors to own shares. A company should only split its stock if it is confident in its long-term growth. Netflix and Meta Platforms have ...

Crispr Therapeutics maintains leadership in gene editing, with shares up 75% YTD and renewed investor interest after positive CTX-310 data. CRSP's in-vivo therapy shows promising early results, ...

Upstart was using artificial intelligence before it became commonplace. Now that companies are embracing AI, Upstart’s growth prospects are bright. This stock has underperformed of late, but the ...

Nike is in the middle of a major turnaround effort, with a top priority being to reignite product innovation. If it starts selling apparel and footwear that draw stronger consumer interest, financial ...

Prediction markets are an increasingly big business, and Wall Street wants in on the action. Intercontinental Exchange, the owner of the New York Stock Exchange, said Tuesday that it plans to invest ...